Japan prepares eighth round of vaccine with self-producing mRNA – Artsen Collectief Foundation

The Japanese government has announced that it will provide an eighth corona vaccine to the elderly from October. The seventh injection was taken by about 40% of the target group.

What is new in the eighth round of injections is that self-replicating RNA “vaccines” developed in Japan by Arcturus Therapeutics and Meiji Seika Pharma will also be used. The KP.3 variant of Sars-CoV-2 is currently circulating in Japan.

Self-produced vaccines are genetic vaccines derived from an RNA virus (1) that can undergo an additional propagation method. mRNA vaccines have one mechanism of replication in common: multiple spike proteins can be produced from a single mRNA. The self-producing mRNA vaccines contain an element (RNA to RNA polymerase of the VEEV virus) that copies the spiked portion of the mRNA. This additional amplification step allows a small amount of mRNA to generate a large amount of protein spike.

This is the danger of innovation complications associated with mRNA vaccines also be multiplied. For example, the dosage becomes even more difficult to control than it already was with the mRNA vaccines. Also, there seems to be little control over where proliferation occurs if the vaccine escapes from the injection site, which usually occurs to a greater or lesser extent. less (2). Thirdly, the question is how long the spike protein will be produced in the body. With current mRNA vaccines, this is already much longer than originally thought, and with an additional amplification step it could be much longer (2).

It’s like playing with fire. Unexpected effects are expected. A few questions that might be asked:

• What is the effect of antibodies against viral RNA polymerase, which are also formed?
• What is the effect of the negative strand RNA produced as an intermediate step?
• Is there interaction with other viruses, for example through recombination (3)?
• Are there other RNAs present in the cell that are also being replicated?
• How much DNA contamination is present in these new RNA products?
• Are the mRNAs themselves infectious under certain conditions?

These types of questions are impossible to answer in a short and short time test. It is not without reason that the safety requirements for genetic products are much stricter than for other products. And this product is obviously a genetic product.

We are slowly finding out how the pharmaceutical industry worksso claims of safe and effective We must ignore (4.5) for the moment.

There is a struggle in Japan itself. Including from National Coalition to Stop mRNA Vaccinesa group of doctors, researchers, politicians and citizens who form this coalition Stad-mrna.com established. The coalition plans to file a lawsuit against the Japanese government this month, specifically targeting the use of self-produced vaccines.

The Doctors Collective calls for an end to the use of mRNA vaccines due to the large number of side effects, including severe, unexplained mortality, unexplained birth defects and low efficacy. The Doctors Collective also recommends caution with new types of mRNA vaccines until their safety has been thoroughly, independently and transparently tested.

References

1. Review: Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021 April; 28(3-4):117-129. doi: 10.1038/s41434-020-00204-y. Epub 2020 Oct 22. PMID: 33093657; PMCID: PMC7580817.
2. Review: Pateev I, Seregina K, Ivanov R, Reshetnikov V. Biodistribution of RNA vaccines and their products: Evidence from Human and Animal Studies. Biomedicines. 2023 December 26; 12(1):59. doi: 10.3390/biomedicines12010059. PMID: 38255166; PMCID: PMC10812935.
3. Hick TAH, Geertsema C, Nguyen W, Bishop CR, van Oosten L, Abbo SR, Dumenil T, van Kuppeveld FJM, Langereis MA, Rawle DJ, Tang B, Yan K, van Oers MM, Suhrbier A, Pijlman GP. The safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo. Suggest Ther. 2024 Jun 17:S1525-0016(24)00401-5. doi: 10.1016/j.ymthe.2024.06.019. Epub ahead of print. PMID: 38894543.
4. Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, Yagi Y, Kurosawa T, Greener B, Zhang Y, Walson JL. Immunogenicity and safety of an escalating dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicenter, randomized, controlled, phase 3, nonrandomized trial. Lancet Infect Dis. 2024 April; 24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20. PMID: 38141632.
5. Ho NT, Hughes SG, Ta VT, Phan LT, Do Q, Nguyen TV, Pham ATV, Thi Ngoc Dang M, Nguyen LV, Trinh QV, Pham HN, Chu MV, Nguyen TT, Luong QC, Tuong Le VT, Nguyen TV , Tran LT, Thi Van Luu A, Nguyen AN, Nguyen NT, Vu HS, Edelman JM, Parker S, Sullivan B, Sullivan S, Ruan Q, Clemente B, Luk B, Lindert K, Berdieva D, Murphy K, Sekulovich R , greener B, Smolenov I, Chivukula P, Nguyen VT, Nguyen XH. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phases 1, 2, 3a and 3b randomized, controlled trials. Nat Comn. 2024 May 14; 15(1):4081. doi: 10.1038/s41467-024-47905-1. PMID: 38744844; PMCID: PMC11094049.